Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age? Michael DrummondMark Sculpher Editorial 11 October 2012 Pages: 107 - 108
Sociodemographic Differences in Quality of Life in Rheumatoid Arthritis Erik J. GroesslTheodore G. GaniatsAndrew J. Sarkin Leading Article 11 October 2012 Pages: 109 - 121
Differential Effects of Atypical versus Typical Antipsychotic Medication on Earnings of Schizophrenia Patients David SalkeverEric SladeMustafa Karakus Original Research Article 11 October 2012 Pages: 123 - 139
Combination Vaccine Against Invasive Meningococcal B and Pneumococcal Infections Jasper M. BosHans C. RümkeMaarten J. Postma Original Research Article 11 October 2012 Pages: 141 - 153
A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease Mark LamotteLieven AnnemansMaria Kubin Original Research Article 11 October 2012 Pages: 155 - 169
The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia Rachael L. DiSantostefanoAndrea K. BiddleJohn P. Lavelle Original Research Article 11 October 2012 Pages: 171 - 191
Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries Antoine LafumaAntoine BrézinGilles Berdeaux Original Research Article 11 October 2012 Pages: 193 - 205
How Much is the Cost of Visual Impairment Catherine MeadsChris Hyde Commentary 11 October 2012 Pages: 207 - 209
How Much is the Cost of Visual Impairment: the Author’s Reply Antoine Lafuma Correspondence 11 October 2012 Pages: 210 - 210